pretickt

Is CRSP a good stock to buy?

CRISPR Therapeutics AG · end-of-day data as of Nov 13, 2026

CRISPR Therapeutics
CRSP · $4.1B
$42.24-0.9%
Nov 13, 2026 · close
$50$60SepOctNov9:3016:003 months -20.3%Nov 13 · close
▲ 4
  • PT$72.45 +71.5%
  • ConsensusBuy · 23
  • Bollingerbelow lower
  • Sector▲ +15.9%
Neutral
  • Earnings in90d
  • RSI32
  • Support-7.6%
  • Resistance+0.3%
  • Off 52w high-33.4%
  • Volume1.2x
  • News0.00
  • Trendsideways
  • 52w range$42–$63
  • ATR+6.3%
  • Off ATH-80.8%
▼ 4
  • FCF yield-9.3%
  • Insiders-$4.88M
  • MAs0 of 4
  • MACD-0.81

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is CRISPR Therapeutics a good stock to buy?

CRISPR Therapeutics is strong on 1 of the 5 questions about the business; weak on advantage, economics, execution and fragility. With a loss over the last 12 months, CRISPR Therapeutics has no P/E ratio (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage easy to copy
  3. Economics losing money
  4. Execution misses
  5. Fragility fragile
  6. Price below its peers
DemandDo people want more of what it sells?growing

CRSP sales growth revenue growth

+100%a year, for the last 3 years

CRISPR Therapeutics' sales grew 100% a year for 3 years, to $3.51M in fiscal 2025.

CRSP competitors

pretickt analysis-33%its sales in 12 months, on a year before

CRISPR Therapeutics' sales fell 33% in the 12 months to Sep 30, 2026; Alnylam's grew 56%, Incyte's grew 25%, Twist Bioscience's grew 22% and Bio-Techne's grew 1%.

Advantage moatIs it hard to copy?easy to copy

CRSP margin on each sale gross margin

-677%left after making the product

CRISPR Therapeutics kept -677% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 72%.

EconomicsDoes it make good money?losing money

CRSP cash generated free cash flow

-$379Mcash left after investing, last 12 months

CRISPR Therapeutics burned $379M of cash in the 12 months to Sep 30, 2026, after its investments.

ExecutionDoes it deliver what it promises?misses

CRSP earnings vs estimates

2 of 6quarters above the analysts' estimate

CRISPR Therapeutics beat the analysts' profit estimate in 2 of 6 quarters, the latest on Nov 2, 2026; 2 quarters with one-time gains or charges are left out.

CRSP insider selling

-$17.94Msold, net, by its executives in 12 months

CRISPR Therapeutics' executives and directors sold a net $17.94M of shares in the 12 months to Nov 13, 2026; none bought.

CRSP number of employees

-84%fewer people in a year

CRISPR Therapeutics had 63 employees at the end of fiscal 2025, 84% fewer than a year before.

Fragility risksCould something break it?fragile

CRSP financial health Altman Z-score

1.9Altman Z-score, safe above 3

CRISPR Therapeutics' Altman Z-score is 1.9 (Nov 13, 2026), between 1.8 and 3, the grey zone.

CRSP quality checks Piotroski score

2 of 9checks passed

CRISPR Therapeutics passes 2 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on profit, cash from operations, long-term debt, the current ratio, new shares, gross margin and sales for its assets.

CRSP shareholders institutional ownership

pretickt analysis
  • Ark Investment Management9.8% ▼
  • BlackRock8.7% ▲
  • Orbis Allan Gray5.6% ▼
560institutions hold it; the largest sold shares

560 institutions hold 80% of CRISPR Therapeutics' shares (Jun 30, 2026); BlackRock added shares that quarter, Ark Investment Management and Orbis Allan Gray sold some.

Price valuationIs the price reasonable?below its peers

CRSP price vs profit P/E ratio

—it lost money in 12 months: no P/E

CRISPR Therapeutics has no P/E ratio: it lost money over the 12 months to Sep 30, 2026.

CRSP price vs assets price to book

2.5×times what its assets are worth on paper

CRISPR Therapeutics trades at 2.5 times its book value (Nov 13, 2026); its competitors' median is 5.7.

CRSP analysts' target price target

+72%to their average target

Analysts' average price target for CRISPR Therapeutics is $72.45, 72% above the Nov 13, 2026 close of $42.24.

What is CRISPR Therapeutics' P/E ratio?

CRISPR Therapeutics has no P/E ratio: it lost money over the 12 months to Sep 30, 2026. CRISPR Therapeutics trades at 2.5 times its book value (Nov 13, 2026); its competitors' median is 5.7.

Who are CRISPR Therapeutics' biggest competitors?

pretickt compares CRISPR Therapeutics with Twist Bioscience, Bio-Techne, Alnylam and Incyte. CRISPR Therapeutics' sales fell 33% in the 12 months to Sep 30, 2026; Alnylam's grew 56%, Incyte's grew 25%, Twist Bioscience's grew 22% and Bio-Techne's grew 1%.

Are insiders selling CRISPR Therapeutics stock?

CRISPR Therapeutics' executives and directors sold a net $17.94M of shares in the 12 months to Nov 13, 2026; none bought.

Who owns CRISPR Therapeutics stock?

560 institutions hold 80% of CRISPR Therapeutics' shares (Jun 30, 2026); BlackRock added shares that quarter, Ark Investment Management and Orbis Allan Gray sold some.

How many employees does CRISPR Therapeutics have?

CRISPR Therapeutics had 63 employees at the end of fiscal 2025, 84% fewer than a year before.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.